Christopher Sakellis, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Umbilicus | 1 | 2015 | 41 | 0.530 |
Why?
|
| Hernia, Abdominal | 1 | 2015 | 53 | 0.520 |
Why?
|
| Positron-Emission Tomography | 11 | 2022 | 6234 | 0.520 |
Why?
|
| Fluorodeoxyglucose F18 | 10 | 2022 | 2016 | 0.480 |
Why?
|
| Radiopharmaceuticals | 9 | 2022 | 2645 | 0.330 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2019 | 20129 | 0.310 |
Why?
|
| Melanoma | 2 | 2015 | 5510 | 0.180 |
Why?
|
| Cyclobutanes | 1 | 2020 | 59 | 0.180 |
Why?
|
| Carboxylic Acids | 1 | 2020 | 97 | 0.170 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2013 | 300 | 0.170 |
Why?
|
| Octreotide | 1 | 2018 | 145 | 0.150 |
Why?
|
| Receptors, Somatostatin | 1 | 2018 | 129 | 0.150 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 4851 | 0.150 |
Why?
|
| Nuclear Medicine | 1 | 2018 | 233 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 20822 | 0.120 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 665 | 0.120 |
Why?
|
| Kidney Neoplasms | 3 | 2019 | 4262 | 0.120 |
Why?
|
| Radiotherapy | 2 | 2018 | 1533 | 0.120 |
Why?
|
| Diagnostic Imaging | 2 | 2017 | 3507 | 0.100 |
Why?
|
| Colon | 1 | 2019 | 1772 | 0.100 |
Why?
|
| Diagnosis, Differential | 5 | 2020 | 12959 | 0.090 |
Why?
|
| Lymphoma, Follicular | 1 | 2013 | 435 | 0.090 |
Why?
|
| Barium Sulfate | 1 | 2009 | 180 | 0.080 |
Why?
|
| Pancreatitis | 1 | 2015 | 1092 | 0.080 |
Why?
|
| Genital Neoplasms, Female | 1 | 2014 | 523 | 0.080 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 1353 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2529 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2013 | 1180 | 0.070 |
Why?
|
| Leukemia | 1 | 2012 | 1511 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2018 | 6256 | 0.060 |
Why?
|
| Lymphoma | 1 | 2012 | 1877 | 0.060 |
Why?
|
| Tissue Distribution | 2 | 2018 | 2327 | 0.050 |
Why?
|
| Contrast Media | 2 | 2019 | 5300 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 9239 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 7279 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2015 | 4445 | 0.040 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 57776 | 0.040 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 2019 | 136 | 0.040 |
Why?
|
| Consent Forms | 1 | 2018 | 53 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 9274 | 0.040 |
Why?
|
| Image Enhancement | 1 | 2009 | 2921 | 0.040 |
Why?
|
| Humans | 17 | 2022 | 744343 | 0.040 |
Why?
|
| Neoplasms | 3 | 2018 | 21683 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 11124 | 0.040 |
Why?
|
| Intestinal Neoplasms | 1 | 2018 | 319 | 0.030 |
Why?
|
| Artifacts | 2 | 2018 | 1904 | 0.030 |
Why?
|
| Radioimmunotherapy | 1 | 2013 | 91 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 5686 | 0.030 |
Why?
|
| Female | 7 | 2022 | 380194 | 0.030 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 594 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 11031 | 0.030 |
Why?
|
| Remission Induction | 1 | 2017 | 2386 | 0.030 |
Why?
|
| Urinary Tract | 1 | 2013 | 309 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2013 | 2031 | 0.020 |
Why?
|
| Necrosis | 1 | 2013 | 1643 | 0.020 |
Why?
|
| Male | 6 | 2020 | 350118 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 1333 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2013 | 709 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 814 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2018 | 77449 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2017 | 2616 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2009 | 1590 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2013 | 1809 | 0.020 |
Why?
|
| Stomach | 1 | 2009 | 697 | 0.020 |
Why?
|
| Adult | 5 | 2019 | 214055 | 0.010 |
Why?
|
| Middle Aged | 5 | 2017 | 213383 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 35421 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 6895 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2013 | 2575 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2009 | 1381 | 0.010 |
Why?
|
| Aged | 4 | 2017 | 163280 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2009 | 3913 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 2009 | 1415 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 5256 | 0.010 |
Why?
|
| Intestines | 1 | 2009 | 1924 | 0.010 |
Why?
|
| Disease Progression | 1 | 2016 | 13284 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 12354 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 2016 | 5181 | 0.010 |
Why?
|
| Lung | 1 | 2013 | 9856 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 11524 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 8863 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2013 | 63114 | 0.000 |
Why?
|
| Brain | 1 | 2013 | 26385 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2009 | 53288 | 0.000 |
Why?
|
| Young Adult | 1 | 2009 | 56430 | 0.000 |
Why?
|